Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Long awaited data from the clinical investigation of bladder cancer in both the neoadjuvant and adjuvant settings were released in 2011, setting the stage for the next generation of work in this area. The findings of a number of studies provide the first steps towards a personalized approach to this disease.
Contemporary treatment guidelines for the localized renal mass are largely driven by expert opinion and retrospective observational data. Three articles published in 2011 add important information to the existing body of literature, enabling improved objectification of risk and individualization of clinical tradeoff decisions for patients presenting with localized renal tumors.
2011 was a breakthrough year for the treatment of castration-resistant prostate cancer. The encouraging results of two large clinical trials were reported, as well as data identifying a number of promising new therapeutic targets. Bone-modulating agents continued to show potential for the prevention of skeletal events.
Urinary incontinence is a common and distressing condition. Although management of stress urinary incontinence can be challenging, new innovations in 2010 have improved the range of therapeutic options for both men and women.
Gleason sum upgrading (GSU) is common in patients with organ-confined prostate cancer. Studies in 2010 have identified GSU predictors and examined the role of GSU in patients with prostate cancer, but several clinical applications for GSU have been suggested—has its clinical importance in daily practice been inflated?
Noteworthy findings over the past year have included the growing importance of nephron-sparing surgery, a promising new drug for metastatic renal cell carcinoma (RCC) and a nomogram to assist treatment decision making in elderly patients—all important principles in the treatment of RCC.
Treatment for patients with urinary tract stone disease includes removal of the stones and prevention of their recurrence. However, the optimal therapy for stone disease is currently debated. How far has the field advanced in terms of treatment and understanding of stone formation?
